• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulation in patients with atrial fibrillation and chronic kidney disease: clinical complexity beyond thromboembolism.

作者信息

Buoninfante Giovanni, Basili Stefania, Romiti Giulio Francesco

机构信息

Department of Translational and Precision Medicine, Sapienza - University of Rome, Rome, Italy.

Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.

出版信息

Intern Emerg Med. 2024 Oct;19(7):1797-1799. doi: 10.1007/s11739-024-03733-1. Epub 2024 Aug 3.

DOI:10.1007/s11739-024-03733-1
PMID:39096349
Abstract
摘要

相似文献

1
Anticoagulation in patients with atrial fibrillation and chronic kidney disease: clinical complexity beyond thromboembolism.心房颤动合并慢性肾脏病患者的抗凝治疗：血栓栓塞之外的临床复杂性
Intern Emerg Med. 2024 Oct;19(7):1797-1799. doi: 10.1007/s11739-024-03733-1. Epub 2024 Aug 3.
2
Systemic anticoagulation in progressive chronic kidney disease and atrial fibrillation.进展性慢性肾脏病与心房颤动中的全身抗凝治疗
J Int Med Res. 2025 Apr;53(4):3000605251333306. doi: 10.1177/03000605251333306. Epub 2025 Apr 25.
3
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.非维生素 K 依赖性口服抗凝剂（NOACs）在伴有心房颤动的慢性肾脏病患者中的应用。
Thromb Res. 2017 Jul;155:38-47. doi: 10.1016/j.thromres.2017.04.027. Epub 2017 May 4.
4
Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk.心房颤动与慢性肾脏病：降低血栓栓塞风险的治疗性抗凝方案综述
Clin Cardiol. 2018 Oct;41(10):1395-1402. doi: 10.1002/clc.23085. Epub 2018 Oct 25.
5
[Anticoagulant therapy for patients with atrial fibrillationin in special situations: diabetes mellitus and/or chronic kidney disease].
Kardiologiia. 2018;58(S7):4-10.
6
Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials.慢性肾脏病、抗凝治疗非瓣膜性心房颤动患者的治疗时间范围与不良临床结局：SPORTIF试验的观察结果
EBioMedicine. 2016 Jun;8:309-316. doi: 10.1016/j.ebiom.2016.04.013. Epub 2016 Apr 19.
7
Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.心房颤动合并慢性肾脏病患者的抗凝治疗：疗效与安全性。
Expert Opin Drug Saf. 2013 Jan;12(1):53-63. doi: 10.1517/14740338.2013.732569. Epub 2012 Oct 24.
8
Open Issues in the Management of Otcagerian Patients with Atrial Fibrillation and Chronic Kidney Disease: Are we Ready for Left Atrial Appendage Occlusion (LAAO) as First-Line Therapy for Thromboembolic Risk Prevention?老年心房颤动合并慢性肾脏病患者管理中的未决问题：我们是否准备好将左心耳封堵术（LAAO）作为预防血栓栓塞风险的一线治疗方法？
Cardiovasc Drugs Ther. 2024 Jun;38(3):401-403. doi: 10.1007/s10557-024-07554-4. Epub 2024 Jan 26.
9
New oral anticoagulants in patients with chronic kidney disease.慢性肾病患者使用新型口服抗凝药的情况
Nefrologia. 2017 May-Jun;37(3):244-252. doi: 10.1016/j.nefro.2016.08.006. Epub 2016 Dec 9.
10
Role of the left atrial appendage closure in preventing thromboembolism in atrial fibrillation: what is the importance for chronic kidney disease patients?左心耳封堵在预防心房颤动血栓栓塞中的作用：对慢性肾脏病患者有何重要性？
J Nephrol. 2024 Jun;37(5):1197-1200. doi: 10.1007/s40620-024-01944-5. Epub 2024 Apr 24.

本文引用的文献

1
Safety and effectiveness of oral anticoagulants in patients with atrial fibrillation and stage 4 chronic kidney disease: a real-world experience.口服抗凝剂在心房颤动合并4期慢性肾脏病患者中的安全性和有效性：一项真实世界研究。
Intern Emerg Med. 2024 Sep;19(6):1645-1652. doi: 10.1007/s11739-024-03658-9. Epub 2024 Jun 28.
2
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.2024 AHA/ACC/AMSSM/HRS/PACES/SCMR 肥厚型心肌病管理指南：美国心脏协会/美国心脏病学会联合临床实践指南委员会的报告。
Circulation. 2024 Jun 4;149(23):e1239-e1311. doi: 10.1161/CIR.0000000000001250. Epub 2024 May 8.
3
Initial eGFR Changes with SGLT2 Inhibitor in Patients With Type 2 Diabetes and Associations With the Risk of Abnormal Serum Potassium Level.SGLT2 抑制剂治疗 2 型糖尿病患者时的初始 eGFR 变化及其与血清钾异常风险的关系。
J Am Heart Assoc. 2024 May 7;13(9):e033236. doi: 10.1161/JAHA.123.033236. Epub 2024 Apr 30.
4
Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study.2000 年至 2022 年期间，丹麦全国范围内基于人群的队列研究中，房颤及其并发症的终生风险的时间趋势。
BMJ. 2024 Apr 17;385:e077209. doi: 10.1136/bmj-2023-077209.
5
Atrial fibrillation: epidemiology, screening and digital health.心房颤动：流行病学、筛查与数字健康。
Lancet Reg Health Eur. 2024 Feb 1;37:100786. doi: 10.1016/j.lanepe.2023.100786. eCollection 2024 Feb.
6
Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF.临床风险表型对心房颤动管理和自然史的影响：GLORIA-AF 研究报告。
J Am Heart Assoc. 2023 Oct 17;12(20):e030565. doi: 10.1161/JAHA.123.030565. Epub 2023 Oct 10.
7
Anticoagulation in chronic kidney disease: current status and future perspectives.慢性肾脏病中的抗凝治疗：现状与未来展望。
J Thromb Haemost. 2024 Feb;22(2):323-336. doi: 10.1016/j.jtha.2023.09.020. Epub 2023 Sep 29.
8
Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation.诊断心房颤动后特定病因死亡率的时间趋势。
Eur Heart J. 2023 Nov 7;44(42):4422-4431. doi: 10.1093/eurheartj/ehad571.
9
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.直接口服抗凝剂与华法林在肾功能谱中的比较：来自 COMBINE AF 的患者水平网络荟萃分析。
Circulation. 2023 Jun 6;147(23):1748-1757. doi: 10.1161/CIRCULATIONAHA.122.062752. Epub 2023 Apr 12.
10
Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry.房颤患者遵循房颤更佳治疗（ABC）路径与主要结局风险：来自前瞻性GLORIA-AF注册研究的事后分析
EClinicalMedicine. 2022 Nov 24;55:101757. doi: 10.1016/j.eclinm.2022.101757. eCollection 2023 Jan.